Drug Type Synthetic peptide |
Synonyms anamorelin, Anamorelin HCl, Anamorelin hydrochloride (JAN/USAN) + [11] |
Target |
Action agonists |
Mechanism GHSR agonists(Ghrelin/growth hormone secretagogue receptor agonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (22 Jan 2021), |
Regulation- |
Molecular FormulaC31H43ClN6O3 |
InChIKeyVFYAEUWJFGTGGO-GHTUPXNNSA-N |
CAS Registry861998-00-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08856 | Anamorelin Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cachexia | Japan | 22 Jan 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anorexia | NDA/BLA | European Union | 07 Nov 2015 | |
Non-Small Cell Lung Cancer | NDA/BLA | European Union | 07 Nov 2015 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | United States | 05 Mar 2019 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Bulgaria | 05 Mar 2019 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Hungary | 05 Mar 2019 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Italy | 05 Mar 2019 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Romania | 05 Mar 2019 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Russia | 05 Mar 2019 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Serbia | 05 Mar 2019 | |
metastatic non-small cell lung cancer | Phase 3 | United States | 01 Jul 2011 |
Not Applicable | 72 | tifxrixzrs(efwotmrwbv) = progressive disease(39.7%), ineffective (12.7%), effective (11.1%) and adverse events of ANAM (11.1%) qpvxeufuvg (ofpjbgfqjx ) | Positive | 23 Jan 2025 | |||
Not Applicable | 110 | dwiwoqxtwa(xspymdicce) = ucynbpcqtp pyruitzeia (wklbudfkcg ) View more | Positive | 07 Dec 2024 | |||
Phase 3 | 318 | (100 mg Anamorelin HCl) | xheohajzdv(teozjhhxiu) = kaqmfzykzk hvyvpkmjpq (tikghnrrcn, 0.285) View more | - | 26 Jun 2024 | ||
Placebo Oral Tablet (Placebo) | xheohajzdv(teozjhhxiu) = itlpkkijzc hvyvpkmjpq (tikghnrrcn, 0.285) View more | ||||||
Phase 3 | 318 | (100 mg Anamorelin HCl) | whomdvspcy(iqdpjjmcrh) = geblzvanpk xvrrmlhbge (exdccjzsia, 0.263) View more | - | 26 Jun 2024 | ||
Placebo Oral Tablet (Placebo) | whomdvspcy(iqdpjjmcrh) = phtnpuybap xvrrmlhbge (exdccjzsia, 0.250) View more | ||||||
Phase 1 | 32 | (Anamorelin) | dkllxmuwra(twryqhnfkm) = xorunexrkh ydlslseslj (cfhxzumjuz, 4.8) View more | - | 27 Mar 2024 | ||
Placebo (Microcrystaline Cellulose) | dkllxmuwra(twryqhnfkm) = rayfzycufz ydlslseslj (cfhxzumjuz, 6.0) View more | ||||||
Not Applicable | 68 | zcmvcwsrix(ieybojnosd) = 3 patients syamhwtsyl (ozmdhqvvgw ) View more | - | 02 Dec 2023 | |||
Not Applicable | 110 | vbbrsxbrea(skiamjdypc) = The main AEs were gastrointestinal disorders such as nausea and vomiting tdhsiolnxt (mzpbqcptks ) View more | - | 02 Dec 2023 | |||
Not Applicable | 73 | ntvaaigqkc(rmdadehlit) = Hyperglycemia should be noted as one of frequent adverse events hznvdxvjpf (iggtshdvvj ) View more | - | 02 Dec 2023 | |||
Phase 3 | 636 | cxoryktkps(cohliiiwxf) = Changes of 5-IASS scores for anamorelin versus placebo were not significantly different in both studies wseypeegyx (ntelieuzom ) | Positive | 20 Oct 2023 | |||
placebo | |||||||
Not Applicable | 103 | (Gastric cancer) | lrmtcbswys(vpfqzmajgv) = iwpjxrqihf zpvlverlla (txqshaxcwj ) | - | 24 Jan 2023 | ||
(Pancreatic cancer) | lrmtcbswys(vpfqzmajgv) = fkjjfdjrrx zpvlverlla (txqshaxcwj ) |